The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation
Open accessAbstract
Objectives The purpose of this study was to assess the safety and efficacy of left atrial appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible for warfarin therapy.Background The PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that LAA closure with the Watchman device (Boston Scientific, Natick, Massachusetts) was noninferior to warfarin therapy. However, the PROTECT AF trial only included patients who were candidates for warfarin, and even patients randomly assigned to the LAA closure arm received concomitant warfarin for 6 weeks after Watchman implantation.Methods A multicenter, prospective, nonrandomized study was conducted of LAA closure with the Watchman device in 150 patients with nonvalvular AF and CHADS₂ (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke or transient ischemic attack) score ≥1, who were considered ineligible for warfarin. The primary efficacy endpoint was the combined events of ischemic stroke, hemorrhagic stroke, systemic embolism, and cardiovascular/unexplained death.Results The mean CHADS₂ score and CHA₂DS₂-VASc (CHADS₂ score plus 2 points for age ≥75 years and 1 point for vascular disease, age 65 to 74 years, or female sex) score were 2.8 ± 1.2 and 4.4 ± 1.7, respectively. History of hemorrhagic/bleeding tendencies (93%) was the most common reason for warfarin ineligibility. Mean duration of follow-up was 14.4 ± 8.6 months. Serious procedure- or device-related safety events occurred in 8.7% of patients (13 of 150 patients). All-cause stroke or systemic embolism occurred in 4 patients (2.3% per year): ischemic stroke in 3 patients (1.7% per year) and hemorrhagic stroke in 1 patient (0.6% per year). This ischemic stroke rate was less than that expected (7.3% per year) based on the CHADS₂ scores of the patient cohort.Conclusions LAA closure with the Watchman device can be safely performed without a warfarin transition, and is a reasonable alternative to consider for patients at high risk for stroke but with contraindications to systemic oral anticoagulation. (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology [ASAP]; NCT00851578).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“occlusion may also reduce stroke risk in patients with contraindications to OAC. 454,455”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [454]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors Task Force Members, Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,823
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors Task Force Members, Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,929
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · cited 1×
“In the AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Strokes in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment) study, warfarin-ineligible patients were randomly allocated to either aspirin or the factor Xa inhibitor, apixaban (21).”
MethodHolmes, D. R., Reddy, V. Y., Turi, Z. G., Doshi, S. K., Sievert, H., Buchbinder, M., Mullin, C. M., & Sick, P. B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61343-x · Cited by 2,242
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102 · cited 2×
“Clopidogrel has been reported to reduce ischemic stroke by 32% (13).”
BackgroundMethodMant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
Wann, L. S., Curtis, A. B., January, C. T., Ellenbogen, K. A., Lowe, J. E., Estes, N. A. M., Page, R. L., Ezekowitz, M. D., Slotwiner, D. J., Jackman, W. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3181fa3cf4 · Cited by 1,338
Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
Hylek, E. M., Go, A. S., Chang, Y., Jensvold, N. G., Henault, L. E., Selby, J. V., & Singer, D. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022913 · Cited by 1,275
Hylek, E. M., Evans‐Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007) · Circulation · doi:10.1161/circulationaha.106.653048 · Cited by 1,063
Clinical interpretation and use of stroke scales
Kasner, S. E. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70495-1 · Cited by 947
Safety of Percutaneous Left Atrial Appendage Closure
Reddy, V. Y., Holmes, D. R., Doshi, S. K., Neužil, P., & Kar, S. (2011) · Circulation · doi:10.1161/circulationaha.110.976449 · Cited by 863
Kim, M. H., Johnston, S. S., Chu, B. C., Dalal, M. R., & Schulman, K. L. (2011) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.958165 · Cited by 798
Gage, B. F., van Walraven, C., Pearce, L., Hart, R. G., Koudstaal, P. J., Boode, B. S. P., & Petersen, P. (2004) · Circulation · doi:10.1161/01.cir.0000145172.55640.93 · Cited by 749
2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation
Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., & Kirchhof, P. F. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.11.003 · Cited by 687
Identifying Patients at High Risk for Stroke Despite Anticoagulation
Lip, G. Y. H., Frison, L., Halperin, J. L., & Lane, D. A. (2010) · Stroke · doi:10.1161/strokeaha.110.590257 · Cited by 493
The increasing incidence of anticoagulant-associated intracerebral hemorrhage
Flaherty, M. L., D, B. M. K. M., Woo, D., Kleindorfer, D., Alwell, K., Sekar, P., Moomaw, C. J., Haverbusch, M. A., & Broderick, J. P. (2007) · Neurology · doi:10.1212/01.wnl.0000250340.05202.8b · Cited by 477
Wann, L. S., Curtis, A. B., Ellenbogen, K. A., Estes, N. A. M., Ezekowitz, M. D., Jackman, W. M., January, C. T., Lowe, J. E., Page, R. L., Slotwiner, D. J., et al. (2011) · Heart Rhythm · doi:10.1016/j.hrthm.2011.01.032 · Cited by 394
Block, P. C., Burstein, S., Casale, P. N., Kramer, P. H., Teirstein, P. S., Williams, D. O., & Reisman, M. (2009) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.05.005 · Cited by 247
Wann, L. S., Curtis, A. B., January, C. T., Ellenbogen, K. A., Lowe, J. E., Estes, N. A. M., Page, R. L., Ezekowitz, M. D., Slotwiner, D. J., Jackman, W. M., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.001 · Cited by 229
Lip, G. Y. H., Andreotti, F., Fauchier, L., Huber, K., Hylek, E. M., Knight, E., Lane, D. A., Levi, M. M., Marín, F. R., Palareti, G., et al. (2011) · EP Europace · doi:10.1093/europace/eur126 · Cited by 224
Lópes, R. D., Al‐Khatib, S. M., Wallentin, L. C., Yang, H., Ansell, J., Bahit, M. C., Caterina, R. D., Dorian, P., Easton, J. D., Erol, Ç., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60986-6 · Cited by 210
Bayard, Y. L., Omran, H., Neužil, P., Thuesen, L., Pichler, M., Rowland, E., Ramondo, A. B., Rużyłło, W., Budts, W., Montalescot, G., et al. (2010) · EuroIntervention · doi:10.4244/eijv6i2a35 · Cited by 175
Önalan, O., & Crystal, E. (2007) · Stroke · doi:10.1161/01.str.0000250166.06949.95 · Cited by 134
Lee, W. C., Lamas, G. A., Balu, S., Spalding, J. R., Wang, Q., & Pashos, C. L. (2008) · Journal of Medical Economics · doi:10.3111/13696990802063425 · Cited by 108
The ACTIVE Steering Committee (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.06.026 · Cited by 99
Mercaldi, C. J., Ciarametaro, M., Hahn, B. A., Chalissery, G., Reynolds, M. W., Sander, S. D., Samsa, G. P., & Matchar, D. B. (2010) · Stroke · doi:10.1161/strokeaha.110.592907 · Cited by 75
Viles-González, J. F., Reddy, V. Y., Petrů, J., Mráz, T., Grossova, Z., Královec, Š., & Neužil, P. (2011) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-011-9613-x · Cited by 53
Flagged first, then by citations
1 of the 31 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Gelder, I. C. V., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., Potter, T. J. R. D., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,594
Metadata
- Authors
- Reddy, V. Y., Möbius-Winkler, S., Miller, M. A., Neuzil, P., Schuler, G., Wiebe, J., Sick, P., & Sievert, H.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Leipzig Heart Institute (DE)
- Cardiovascular Center Frankfurt (DE)
- Krankenhaus Barmherzige Brüder (DE)
- Corresponding author
- Reddy, Vivek Y.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 61
- Issue
- 25
- Pages
- 2551-2556
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2115996784
- Cited by
- 727
- References
- 31
- Citations by year
- 2026: 25 · 2025: 28 · 2024: 46 · 2023: 51 · 2022: 43 · 2021: 57 · 2020: 48 · 2019: 59 · 2018: 61 · 2017: 72 · 2016: 83 · 2015: 75 · 2014: 59 · 2013: 17
- FWCI
- 52.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Boston Scientific
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cardiovascular and Diving-Related Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- left atrial appendage closure, Watchman device, non-valvular atrial fibrillation, stroke prevention, systemic embolism, CHADS2 score, CHA2DS2-VASc score, bleeding risk, procedural safety, ischemic stroke, hemorrhagic stroke, anticoagulation alternatives
- MeSH terms
- Contraindications, Clopidogrel, Administration, Oral, Aged, Aged, 80 and over, Anticoagulants, Feasibility Studies, Female, Follow-Up Studies, Humans, Male, Platelet Aggregation Inhibitors, Prospective Studies, Ticlopidine, Treatment Outcome, Atrial Appendage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
